Tick-Borne Flaviviruses Depress AKT Activity during Acute Infection by Modulating AKT1/2.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
23 09 2020
Historique:
received: 19 06 2020
revised: 17 09 2020
accepted: 18 09 2020
entrez: 26 9 2020
pubmed: 27 9 2020
medline: 10 2 2021
Statut: epublish

Résumé

Tick-borne flaviviruses (TBFVs) are reemerging public health threats. To develop therapeutics against these pathogens, increased understanding of their interactions with the mammalian host is required. The PI3K-AKT pathway has been implicated in TBFV persistence, but its role during acute virus infection remains poorly understood. Previously, we showed that Langat virus (LGTV)-infected HEK 293T cells undergo a lytic crisis with a few surviving cells that become persistently infected. We also observed that

Identifiants

pubmed: 32977414
pii: v12101059
doi: 10.3390/v12101059
pmc: PMC7598186
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Références

Cancer Res. 2001 Aug 1;61(15):5911-8
pubmed: 11479233
Cell Signal. 2011 Dec;23(12):1952-60
pubmed: 21777670
J Virol. 2001 Jul;75(13):6022-32
pubmed: 11390604
Euro Surveill. 2019 Nov;24(47):
pubmed: 31771701
Antioxid Redox Signal. 2011 Jul 1;15(1):1-17
pubmed: 21303257
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Eur J Neurol. 2017 Oct;24(10):1214-e61
pubmed: 28762591
Viruses. 2018 Jun 16;10(6):
pubmed: 29914165
Am J Trop Med Hyg. 2001 Nov;65(5):671-6
pubmed: 11716135
J Virol. 2005 Oct;79(20):12828-39
pubmed: 16188985
mBio. 2016 May 24;7(3):
pubmed: 27222466
Rev Med Virol. 2015 Jul;25(4):205-23
pubmed: 25828437
J Virol Methods. 2001 Mar;92(1):37-44
pubmed: 11164916
Biochem J. 2010 Sep 1;430(2):199-205
pubmed: 20704571
Adv Virus Res. 2003;59:277-314
pubmed: 14696332
J Virol. 2017 Jan 18;91(3):
pubmed: 27881649
J Gen Virol. 2009 Sep;90(Pt 9):2081-5
pubmed: 19474250
Euro Surveill. 2018 Nov;23(45):
pubmed: 30424829
Virology. 2018 Mar;516:147-157
pubmed: 29358114
Cancer Res. 2011 Jul 1;71(13):4720-31
pubmed: 21555366
Cent Eur J Public Health. 2009 Sep;17(3):139-45
pubmed: 20020603
PLoS One. 2012;7(10):e47912
pubmed: 23112871
Antiviral Res. 2013 May;98(2):192-208
pubmed: 23523765
Genes Dev. 2001 Sep 1;15(17):2203-8
pubmed: 11544177
Scand J Infect Dis. 1996;28(3):217-24
pubmed: 8863349
Viruses. 2017 Apr 30;9(5):
pubmed: 28468299
Curr Opin Virol. 2012 Oct;2(5):614-21
pubmed: 23057872
Viruses. 2013 Dec 16;5(12):3192-212
pubmed: 24351799
Arch Virol. 2009;154(5):811-20
pubmed: 19363586
J Virol. 2002 Apr;76(8):3731-8
pubmed: 11907212
J Virol. 2008 May;82(10):4731-41
pubmed: 18337583
Cell Commun Signal. 2019 Nov 21;17(1):154
pubmed: 31752925
Viruses. 2011 Sep;3(9):1739-56
pubmed: 21994804
J Virol. 2013 Jan;87(2):872-81
pubmed: 23115297
Development. 2005 Jul;132(13):2943-54
pubmed: 15930105
Nat Immunol. 2002 Nov;3(11):1090-6
pubmed: 12389041
Neurochem Res. 2009 May;34(5):991-1001
pubmed: 18949556
Genes Dev. 2006 Aug 15;20(16):2238-49
pubmed: 16882970
PLoS Pathog. 2008 Aug 29;4(8):e1000141
pubmed: 18769720
Cell. 2017 May 4;169(4):610-620.e14
pubmed: 28457610
J Virol. 2003 Jan;77(1):25-36
pubmed: 12477807
Cancer Res. 2004 Oct 1;64(19):7002-10
pubmed: 15466193
Vaccine. 2003 Apr 1;21 Suppl 1:S11-8
pubmed: 12628810
Antiviral Res. 2015 Jun;118:148-58
pubmed: 25842996
Clin Infect Dis. 2002 Sep 15;35(6):650-8
pubmed: 12203160
Oncogene. 2003 Dec 8;22(56):8983-98
pubmed: 14663477
Science. 2004 May 28;304(5675):1325-8
pubmed: 15166380
Cell Stem Cell. 2016 Nov 3;19(5):663-671
pubmed: 27524440
mBio. 2015 May 12;6(3):e00553-15
pubmed: 25968648
Euro Surveill. 2008 Jun 26;13(26):
pubmed: 18761916
Cell Death Differ. 2013 Oct;20(10):1341-9
pubmed: 23787999
Virus Res. 2013 Dec 26;178(2):471-7
pubmed: 24177270
Virology. 2008 Apr 25;374(1):170-85
pubmed: 18234265
Virology. 2018 Jan 15;514:98-105
pubmed: 29156399
Nature. 1956 Sep 15;178(4533):581-2
pubmed: 13369466
Curr Opin Virol. 2017 Apr;23:95-101
pubmed: 28486135
Euro Surveill. 2016 Aug 18;21(33):
pubmed: 27562931
J Virol. 2005 Jul;79(13):8388-99
pubmed: 15956583
Cancer Cell. 2008 Dec 9;14(6):458-70
pubmed: 19061837
Sci Signal. 2009 Oct 13;2(92):ra62
pubmed: 19825827
mBio. 2015 Jun 04;6(3):e00614
pubmed: 26045539
Cell Cycle. 2009 Aug 15;8(16):2502-8
pubmed: 19597332

Auteurs

Joshua M Kirsch (JM)

Biology of Vector-Borne Viruses Section, Laboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT 59840, USA.

Luwanika Mlera (L)

Biology of Vector-Borne Viruses Section, Laboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT 59840, USA.

Danielle K Offerdahl (DK)

Biology of Vector-Borne Viruses Section, Laboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT 59840, USA.

Marthe VanSickle (M)

Biology of Vector-Borne Viruses Section, Laboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT 59840, USA.

Marshall E Bloom (ME)

Biology of Vector-Borne Viruses Section, Laboratory of Virology, Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT 59840, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH